$2.96
0.68% yesterday
Nasdaq, Nov 25, 09:46 pm CET
ISIN
US05280R1005
Symbol
AUTL
Sector
Industry

Autolus Therapeutics plc Stock price

$2.98
-1.46 32.88% 1M
-0.94 23.98% 6M
-3.46 53.73% YTD
-1.80 37.66% 1Y
-3.43 53.51% 3Y
-10.56 77.99% 5Y
-22.02 88.08% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.04 1.36%
ISIN
US05280R1005
Symbol
AUTL
Sector
Industry

Key metrics

Market capitalization $793.03m
Enterprise Value $435.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 43.18
P/S ratio (TTM) P/S ratio 78.60
P/B ratio (TTM) P/B ratio 1.66
Revenue growth (TTM) Revenue growth 82.71%
Revenue (TTM) Revenue $10.09m
EBIT (operating result TTM) EBIT $-205.81m
Free Cash Flow (TTM) Free Cash Flow $-205.61m
Cash position $658.54m
EPS (TTM) EPS $-1.21
P/E forward negative
P/S forward 54.80
EV/Sales forward 30.10
Short interest 3.65%
Show more

Is Autolus Therapeutics plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Autolus Therapeutics plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Autolus Therapeutics plc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Autolus Therapeutics plc forecast:

Buy
100%

Financial data from Autolus Therapeutics plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
10 10
83% 83%
100%
- Direct Costs 7.41 7.41
-
73%
2.68 2.68
-
27%
- Selling and Administrative Expenses 68 68
169% 169%
677%
- Research and Development Expense 133 133
3% 3%
1,316%
-198 -198
21% 21%
-1,966%
- Depreciation and Amortization 7.41 7.41
14% 14%
73%
EBIT (Operating Income) EBIT -206 -206
21% 21%
-2,040%
Net Profit -270 -270
71% 71%
-2,678%

In millions USD.

Don't miss a Thing! We will send you all news about Autolus Therapeutics plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Autolus Therapeutics plc Stock News

Positive
Seeking Alpha
5 days ago
Autolus Therapeutics' AUCATZYL, approved by the FDA for relapsed/refractory B-cell ALL, shows strong potential despite safety concerns. The Company's Obe-cel family and oncology pipeline include multiple catalysts for 2025, expanding potential indications in autoimmune diseases and hematologic malignancies. AUTL's cash runway of 1.9 years and no financial debt provide a solid financial foundati...
Neutral
Seeking Alpha
14 days ago
Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Olivia Manser - Director-Investor Relations Christian Itin - Chief Executive Officer Rob Dolski - Chief Financial Officer Conference Call Participants James Shin - Deutsche Bank Matthew Phipps - William Blair Sebastiaan van der Schoot - VLK Hanze Zu - Jefferies Gil Blum - N...
Neutral
GlobeNewsWire
18 days ago
AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy) Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL Conference call to be held on November 11 at 08:30 am EST/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press release LONDON, N...
More Autolus Therapeutics plc News

Company Profile

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Christian Itin
Employees 463
Founded 2014
Website www.autolus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today